Page last updated: 2024-09-05

zm 241385 and Parkinsonian Disorders

zm 241385 has been researched along with Parkinsonian Disorders in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, L; Engber, T; Grant, D; Hetu, G; Huang, C; Jin, X; Kumaravel, G; Peng, B; Petter, RC; Phadke, D; Reilly, J; Smits, G; Tam, S; Vu, CB; Zhang, J1
Dziubina, A; GoĊ‚embiowska, K1
Costentin, J; El Yacoubi, M; Vaugeois, JM1
Benwell, K; Cliffe, IA; Dourish, CT; Gillespie, RJ; Knight, AR; Lerpiniere, J; Misra, A; Pratt, RM; Revell, D; Upton, R; Weiss, SM1

Other Studies

4 other study(ies) available for zm 241385 and Parkinsonian Disorders

ArticleYear
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17

    Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain; Catalepsy; Heterocyclic Compounds, 2-Ring; In Vitro Techniques; Male; Mice; Parkinsonian Disorders; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Structure-Activity Relationship; Triazines; Triazoles

2004
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
    Neurotoxicity research, 2012, Volume: 21, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles

2012
Adenosine A2A receptors and depression.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Depression; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Haloperidol; Mice; Mice, Knockout; Motor Activity; Neurotransmitter Agents; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles

2003
Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mefloquine; Mice; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Phenethylamines; Purines; Pyrimidines; Radioligand Assay; Rats; Triazines; Triazoles

2003